retatrutide ly3437943 triple agonist glp-1 gip glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept From Obesity to Metabolic Health:

Dr Reddys launches oral semaglutide biosimilar tablets, offering broader access to diabetes and weight-loss therapies in India.

Learn about your first injection, common side effects like nausea, practical tips for managing symptoms, and when to contact your healthcare provider during initial treatment.

Called Foundayo, the tablet becomes the second one to receive FDAs green light after Novo Nordisks Wegovy

This is where wellness starts to collide with pharma

#thirdcause

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity